

MEDICAL PROPERTIES OF HYPsizYGUS ULMARIUS (BULL.)**Lena Ahmed Saleh Al-Faqeeh*, Suresh R. Kagne and Mohammad Rafiuddin Naser**Department of Botany, Maulana Azad Collage Dr. Rafiq Zakaria Campus, Rauza Bagh,
Aurangabad (m.s) – 431001.Article Received on
02 April 2018,Revised on 23 April 2018,
Accepted on 13 May 2018,

DOI: 10.20959/wjpr201810-12403

Corresponding Author*Lena Ahmed Saleh Al-
Faqeeh**Department of Botany,
Maulana Azad Collage Dr.
Rafiq Zakaria Campus,
Rauza Bagh, Aurangabad
(m.s) – 431001.**ABSTRACT**

Mushrooms have been used traditionally by ancient people as a source of foods and in their religious activities. Ethnomycology of mushrooms have been reported in many countries including India. Many species of mushrooms provide an excellent source of natural compounds that are useful for the treatment of many diseases. Among these mushrooms, *Hypsizygus ulmaris* (Bull.), is used in many purpose due to it is flavor, texture , nutritional content and medicinal properties. Different types of *Hypsizygus ulmarius* (Bull.) extracts have been showed their activity against bacteria, diabetes, inflammation, tumor and it also provide a good source of antioxidants. The objective of this paper is to provide a review on medical properties of *Hypsizygus Ulmarius* (Bull.) that have been studied.

KEYWORDS: *Hypsizygus ulmarius* (Bull.), antibacterial, antidiabetic, anti-inflammatory, antitumour, antioxidant.

INTRODUCTION

Edible mushrooms are saprophytic macrofungi which belong to class Basidiomycetes. Mushrooms have been used and consumed by ancient people. Traditional knowledgement about mushroom benefits have been transmitted from one generation to another one orally. It has been mention in ancient texts like Vedas. Roman and Chines, think that mushroom have a power for life and strength and it is the God Osiris gift for them. In ancient days in India, China and Iran, people used mushrooms in their religion activities.^[1,2,3,4] Ethnomycology of edible and medicinal mushrooms have been reported in many countries like India and China.^[5,6]

Mushrooms are described as highly tasty and nutritional foods by many populations around

the world.^[7] Mushrooms nutritionally contain carbohydrate, protein, vitamins, essential oil, fibers, unsaturated fatty acid, enzymes and minerals. They are considered as a good source for many bioactive compounds that are used for medical purposes (therapeutic applications).^[8,9,10,11,12,13,14]

Number of mushrooms is approximately 14,000 species and only 14,000 species are described. Among these 14,000 species, only around 2,000 species are safe to consume and 650 species contain medical properties.

In the past thousands of years ago, various types of mushrooms were recognized by human beings as edible and non-edible. They are also identified as a source of food and medical treatment purposes. It is used in traditional treatments in many countries such as Mexico, Japan, China, Africa, Korea and in Central and North American countries. They used them as anti-inflammatory, blood coagulant, wound healing, analgesic agents.^[6,15,16,17]

Mushrooms until today are still under interested conditions particularly as a source of food and due to their nutritional value they play an important role in commerce for many countries around the world.^[18] Also, due to their medical properties many researchers still investigate their medical properties to treat a lot of diseases such as microbial infection, cancer, high cholesterol, oxidant, diabetes, low immune response and inflammatory reactions.^[19,20,21,22]

Among the several numbers of edible mushrooms *Pleurotus* (Fr.) species is known worldwide due to its properties. *Pleurotus* (Fr.) was first cultivated during the first world war in Germany and Kaufner was the first person who documented the cultivation.^[23] Now, many *Pleurotus* (Fr.) species are cultivated around the world because of their short life cycle, rich in mineral content and medical compounds and do not require high technology and expenses.^[24]

Hypsizygus ulmarius (Bull.), commonly called as "Elm oyster" or "Blue oyster" is similar to Oyster mushroom, but differ in morphology and biological efficiency. It is a novel species with very large fruiting body, blue coloured pinheads becoming light white on maturity, high yield repeatable with meaty flavor and attractive keeping quality. This new mushroom variety has attractive shape and fleshy with excellent taste.^[25] This mushroom is one of the important edible mushrooms in the world and it is a popular fungus cultivated in Japan, China and other Asian countries.^[26]

It is used for various purpose due to its remarkable flavor, texture , nutritional content and medicinal properties. Nutritionally, this mushroom contains 23.6% protein, 2.2% fat, 52.4% carbohydrates and 12.9% fiber on dry weight basis. Medically may be considered as good source of phytochemicals that can be used in pharmaceutical medical and food additives. It is known for anti-tumor,cholesterol controlling and cardiovascular properties.^[27,28]

Taxonomy of *Hypsizygus ulmarius* (Bull.)

It is placed in

Phylum: Basidiomycota

Class: Basidiomycetes

Subclass: Agaricomycatideae

Order: Agaricales

Family: Tricholomataceae.^[29]

MEDICAL PROPERTIES OF *HYPsizYGUS ULMARIUS* (BULL.)

Pharmacological research on *Hypsizygus ulmarius* (Bull.) are summarized.

Antibacterial activity

Due to the increasing in numbers of drug resistant bacteria , many researchers try to find new types of antibiotics which have effect on bacteria and also save for human health.

Mushrooms possess several types of natural antifungal and antibacterial compounds to survive in their natural environment. They are rich in antibacterial compounds. Many of the externalized secondary metabolites (extracellular secretions by the mycelium) are known to combat bacteria.^[30,31,32] Several active compounds extracted from mushroom revealed antibacterial activity, namely against *Staphylococcus aureus*, *Bacillus subtilis* and *Escherichia coli*.^[33]

The effect of aqueous extract from fruiting body of *Hypsizygus ulmarius* on five oral bacteria isolates have been studied. *Hypsizygus ulmarius* showed a good inhibition effect against bacterial isolates number 1 and 2 from above five oral bacterial isolates and no significant effect against the rest of three bacterial isolates.^[34]

Antidiabetic properties

Diabetes mellitus is one of the most common disease that infect people around the world. This disease is caused by a defect of β cells of islets of langerhans of the pancreas to produce

insulin that control blood sugar.^[35,36] Approximately 150 million people around the world suffering from diabetes mellitus and it is expected that the number will be increase to 300 million in 2025 and 439 million in 2030.^[37,38] The effect of aqueous extract of fruiting body, mycelia and culture filtrate of *Hypsizygus ulmarius* at two different doses on Streptozotocin-Nicotinamide induced diabetic male Sprague Dawley rat for 30 days has been studied.

Treatment of diabetic rats with two different doses of water extracts (50 mg and 100 mg /kg/body weight twice a day) showed a significant decreased in in the level of glucose and increase the level of insulin and protein in serum of induced diabetic rats in compare to non-treated induced diabetic rats.

Also, water extract showed a reduced effect on activities of marker enzymes Aspartate Aminotransferase, Alanine Aminotransferase and alkaline phosphatase in serum , liver and kidney and on activities of glyconeogenic enzymes, glucose-6-phosphatase and fructose, 1,6-diphosphatase, in liver and kidney in induced diabetic rats when compared to non-treated induced diabetic rats. Activity of glycolytic enzymes, Hexokinase and phosphoglucoisomerase, were increased when diabetic induced mice treated with aqueous extract of *Hypsizygus ulmaris* in compare with non-treated induced diabetic rats.^[39]

Anti-inflammatory and antitumor activity

Inflammation disease is a group of disorders which are characterized by abnormal inflammatory response.^[40] It has been proved over the last years that the inflammation play an important role in many disease such as cancer and other diseases.^[41,42,43]

Cancer is a disease that characterized by irregular proliferation of cells. it is a terrible disease and it is the second killer disease around the world. There are more than 100 types of cancer in the world.^[44,45,46,47,48]

Many mushrooms have been studied for their therapeutic properties such as anticancer, anti-inflammatory, anti-viral, anti-oxidant and as immunomodulating.^[49,50,51,52]

The effect of aqueous ethanolic extracts of both fruiting body and mycelia of *Hypsizygus ulmarius* on induced inflammatory mice at different doses (250, 500 and 1000 mk/kg) were reported. both chronic and acute inflammation were induced in the right hind paw of experimental mice. A decrease in paw thickness of chronic and acute inflammation were showed. The mycelial extract show a higher effect than fruiting body(both in1000mg/kg

dose), in which the percentage of inhibition were 63% and 52% in acute inflammation and 55% and 42% in chronic inflammation, respectively.

Also, a strong antitumor effect of both fruiting body and mycelia of *Hypsizygus ulmarius* ethanolic extracts on Dalton's Lymphoma Ascites induced solid tumor in grain region of male mice at different doses (250,500 and 1000mg/kg) have been reported. The extracts showed a preventative and curative antitumor effect in a dose dependent manner. The aqueous ethanolic extract of mycelia show a higher antitumor effect in compare to fruiting body extract. Percentage of inhibition were 78% and 66 % in preventative effect and 85% and 78% in curative effect at a dose of 1000 mg/kg, respectively.^[28]

Effect of purified exopolysaccharide extracted from mycelia of *Hypsizygus ulmarius* on MCF breast cancer have been studied. Concentration of ethanolic polysaccharide extract was 1mg/ml. Purified extract showed a high anticancer activity against MCF breast cancer and percent of viability of cancer cells was 47.63%.^[53]

Antioxidant properties

Oxidative stress is an event occur as a reason of imbalance between formation and removal of reactive micro molecules. These reactive micro molecules are produced in mammals cells when respond to exogenous damage of cells and may be lead to disease such as cancer, diabetes, cardiovascular disease and many others disorders.^[54,55] A number of studies reports that mushrooms have antioxidant properties.^[56]

The effect of aqueous ethanolic extracts from fruiting body and mycelia of *Hypsizygus ulmarius*, Purified exopolysaccharide ethanol extract and methanol extract from mycelia of *Hypsizygus ulmarius* as antioxidant have been reported. Extracts showed a good antioxidant properties using different tests such as free radical scavenging activity, Hydroxyl radical scavenging activity, ABTS radical – scavenging activity, reducing power, chelating effect on ferrous ion, Inhibition of lipid peroxidation and phenol estimation).^[57,28,53]

CONCLUSION

Hypsizygus ulmarius is a world known mushroom. This species provide an excellent sources of natural products that can be used for the treatment of many diseases. Among researches that focus on the study of this mushroom, it has been provide that *Hypsizygus ulmarius* contain pharmacological compounds that can be used as antibacterial, antidiabetic,

antiinflammarory, anticancer and antioxidant.

REFERENCES

1. Sharma N. Medicinal uses of macrofungi. *Ethnobotany*, 2003; 15: 97-9.
2. Lowy B. New records of mushroom stones from Guatemala *Mycologia*, 1971; 63(5): 983-993.
3. Chang ST., Miles, PG. *Mushrooms: Cultivation Nutritional Value Medicinal Effect and Environmental Impact* (CRC Press): 2004.
4. Subramanian CV. Mushrooms: Beauty diversity relevance. *Current Science*, 1995; 69(12): 986-998.
5. Purukayastha RP. Chandra A. *Manual of Indian edible mushrooms*. Jagendra Book Agency; NewDelhi, India: 1985.
6. Bensky D, Gamble A. *Chinese Materia Medica* 2nd ed., Seattle: Eastl and Press: 1993.
7. Chang ST, Miles, PG. *Edible Mushrooms and Their Cultivation*. Boca Raton: CRC Press: 1989.
8. Alarcón J, Aguila S, Arancibia-Avila P, Fuentes O, Zamorano-Ponce E. Hernández M; Z: *Naturforsch C.*; 2003; 58: 62-64
9. Badalyan SM, Gharibyan NG, Kocharyan AE: Biological Characteristics and Genetic Diversity of several Basidiomycetes Medicinal Mushrooms. *Int. J. Med. Mushr*, 2007; 9: 276-277.
10. Kubo K, Aoki H, Nanba H. Antidiabetic activity in the fruit body of *Grigola frondosa* (Maitake). *Biol. Pharm. Bull*, 1994; 17: 1106-1110.
11. Kües U, Künzler M, Bottoli APF, Walser PJ, Granado JD et al. Fungi in Human and Animal Health. In: Kushwaha RKS (ed.), India: Sci. Publ., Jodhpur: 2003.
12. Lindequist U, Niedermeyer THJ, Jülich WD. Evid Based complement. *Alternat Med*, 2005; 2: 285–299.
13. Pemberton RT. Agglutinins (lectins) from some British higher fungi. *Mycol. Res*, 1994; 98: 277-290.
14. Wang HX, Ng TB, Ooi VEC. Lectins from mushrooms- a review. *Mycol. Res*, 1998; 102: 897-906.
15. Hobbs CH. *Medicinal Mushrooms. An exploration of tradition, healing and culture*. 2nd ed., Santa Cruz, California: Bot. Press: 1995.
16. Gunde-Cimerman N, Cimerman A. *Pleurotus* fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase- Lovastatin. *Exp. Mycol*, 1995; 19: 1-6.

17. Denisova NP. Medicinal Properties of Mushrooms. Russia:St.-Petersburg: 1998.
18. Chang ST. Mushroom Production in South East Asia. Mushroom Newslett Trop, 1980; 4: 5-10.
19. Aletor VA. Compositional Studies on edible tropical specials of mushrooms. Food Chem, 1995; 54: 256–268.
20. Fasidi IO. Studies on *Volvariella esculenta* mass singer, Cultivation on agricultural wastes and proximate composition of stored mushrooms. Food Chem, 1996; 55: 161–163.
21. Barros L, Ferreira MJ, Queiros B, Ferreira ICFR, Baptista P. Total phenols, ascorbic acid, β -carotene and lycopene in Portuguese wild edible mushrooms and their antioxidant activities. Food Chem, 2007; 103: 413–9.
22. Oyetayo VO. Free radical scavenging and antimicrobial properties of extracts of wild mushrooms. Braz J Microbiol, 2009; 40: 380–6.
23. Kaufert F. The biology of *Pleurotu scorticatus* Fries. Minnesota Agricultural Experiment Station Bulletin. 1936; 114.
24. Yildiz S, Yildiz UC, Gezer ED, aneTemiz A. Some lingnocellulosic waste used as raw material in cultivation of the *Pleurotus ostreatus* culture mushroom process Biochem. J, 2002; 301-306.
25. Sumi I, Dr. Geetha D. Physiological and cultural studies on blue oyster mushroom, *Hypsizygu ulmarius* (Bull.:Fr.). Inter. J appli. Puresci. agricult, 2016; 2(6): 33-38.
26. Chang ST. World production of cultivated edible and medicinal mushroom in 1997 with emphasis on *Lentinus edodes*(Berk) Sing. in China. Int. J. Med Mushroom, 1999; 1: 291- 300.
27. Shivashankar M, Premkumari B. Preliminary Qualitative Phytochemical Screening of Edible Mushroom *Hypsizygu ulmarius*. Scie.Techn. Arts Res. J, 2014; 3(1): 122-126.
28. Panavalappil G, Korattuvalappil SR, Mangalathmelathil NN, Meera P, Karattuthodi FZ, Kainoor K J. Antioxidant, Anti-Inflammatory, and Antitumor Activities of Cultured mycelia and Fruiting Bodies of the Elm Oyster Mushroom, *Hypsizygu ulmarius* (Agaricomcyetes). Inter. J. Medi. Mushrooms, 2016; 18(3): 235–244.
29. Kirk PM, Cannon PF, David JC, Staplers JA. Ainsworth and Bisby's Dictionary of the fungi. 9th ed., Oxford: CABI Publ: 2001; 655.
30. Benedict RG, Brady LR. Antimicrobial activity of mushroom metabolites. J Pharmacol Sci, 1972; 61: 1820-1822.
31. Kupra J, Anke T, Oberwinkler G, Schramn G, Steglich W. Antibiotics from basidiomycetes VII. *Crinipellis stipitaria*(Fr.) Pat. J Antibiot, 1979; 32: 130-135.

32. Lindequist U, Teuscher E, Narbe G 1. Neue Wirkstoffe aus Basidiomyceten. *Phytother*, 1990; 11: 139-149.
33. Takazawa H, Tajima F, Miyashita C. An antifungal compound from “Shiitake” (*Lentinus edodes*). *Yakuga Zasshi*, 1982; 102: 489-491.
34. Aarthy K, Deivanai K. Evaluation of antibacterial potentials of some edible mushroom species. *Int. J. Curr. Res. Chem. Pharma.Sci*, 2014; 1(8): 116–121.
35. Rai RD, Sohi. How protein rich are mushrooms. *Indian Hort*, 1998; 33: 2-3.
36. Bahl N. Food value of mushrooms. New Delhi: Oxford & IBH publishing; 2000.
37. Vamsikrishna AN, Ramgopal M, Raman BV, Balaji M. Antidiabetic efficacy of ethanolic extract of *Phragmites vallatoria* on STZ induced diabetic rats. *Int J Pharm Pharm Sci*, 2012; 4 (1): 118-120.
38. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diab. Res. Clin. Prac*, 2010; 87: 4–14.
39. Meera KS , Dr.G Sudha, Rajathi K, Manjusha GV. Antidiabetic effect of aqueous extract of *Hypsizygus ulmarius* on Streptozotocin- Nicotinamide induced diabetic rats. *Asian J Pharm Biol Res*, 2011; 151-157.
40. Hotamisligil GS. Inflammation and metabolic disorders *Nature*, 2006; 444(7121): 860- 867.
41. Mantovani A, Allavena p, Sica A, Balkwill F. Cancer-related inflammation. *Nature*, 2008; 454(7203): 436-444.
42. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. *Nat Rev Cancer*, 2006; 6(1): 24-37.
43. Jose N, Ajith TA, Janardhanan KK. Methanol extract of the oyster mushroom, *Pleurotus florida* inhibits inflammation and platelet aggregation. *Phytother Res*, 2004; 18: 43–6.
44. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, Prognostic and therapeutic targets in cancer. *Canc. Treat. t Revi*, 2005; 31(8): 603–617.
45. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981- 2002. *Journal of Nat Prod*, 2003; 66: 1022-37.
46. Nipun D, Vijay S, Jaykumar B, Kirti SP, Richard L. Antitumor activity of *Dendrophthoe falcate* against Ehrlich Ascites Carcinoma in swiss Albio Mice. *Pharmaceutical Crops*, 2011; 2: 1-7.
47. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics 2003. *Cancer J Clin*, 2003; 53: 5-26.
48. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and

- treatment Cell, 2011; 145(1): 30-38.
49. Jeong Y, Yang B, Jeong S, Kim S, Song C. *Ganoderma applanatum*: A promising mushroom for antitumor and immunomodulating activity. *Phytother. Res*, 2008; 22: 614– 619.
 50. Wong J, Wang H, Ng TB. A haemagglutinin from the medicinal fungus *Cordyceps militaris*. *Biosci. Rep*, 2009; 29: 321–327.
 51. Jones S, Janardhanan KK. Antioxidant and antitumor activity of *Ganoderma lucidum* (Cart. Fr.) P.Karst.-Reishi (Aphyllphoromycetidae) from South India. *Int. J Med. Mushroom*, 2000; 2: 195-200.
 52. Jose N, Ajith TA, Janardhanan KK. Antioxidant, anti-inflammatory and antitumor activities of culinary medicinal mushroom *Pleurotus pulmonarius* (Fr.) (Agaricomycetidae). *Int. J. Med. Mushr*, 2002; 4: 329-335.
 53. Karunagran L, Ramakrishnan B. Comparative study on the production, purification and characterization of exopolysaccharides from Oyster mushrooms, *Pleurotus florida* and *Hypsizygus ulmarius* and their applications. *Proceedings of the 8th International Conference on Mushroom Biology and Mushroom Products (ICMBMP8)*, 2014.
 54. Halliwell B. Antioxidant defense mechanisms: From the beginning to the end (of the beginning). *Free Radic Res*, 1999; 31: 261-272.
 55. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. *J Neurochem*, 2006; 97: 1634-1658.
 56. Ferreira ICFR, Barros L, Abreu RMV. Antioxidants in wild mushrooms. *Curr Med Chem*, 2009; 16: 1543-1560.
 57. Sanjit D, Ramesh CU, Panna D, and Ajay KS. Antioxidant activities of methanolic extracts from ten *Pleurotus* species. *Int. Res. J. Pharm*, 2017; 8(3): 44-49.